PL2595960T3 - Sól i solwaty pochodnej tetrahydroizochinoliny - Google Patents

Sól i solwaty pochodnej tetrahydroizochinoliny

Info

Publication number
PL2595960T3
PL2595960T3 PL11740973.0T PL11740973T PL2595960T3 PL 2595960 T3 PL2595960 T3 PL 2595960T3 PL 11740973 T PL11740973 T PL 11740973T PL 2595960 T3 PL2595960 T3 PL 2595960T3
Authority
PL
Poland
Prior art keywords
solvates
salt
tetrahydroisoquinoline derivative
tetrahydroisoquinoline
derivative
Prior art date
Application number
PL11740973.0T
Other languages
English (en)
Inventor
Thomas David Mccarthy
Peter Michael Kelly
Craig James Stewart Boyle
Alexander Redvers Eberlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2595960T3 publication Critical patent/PL2595960T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL11740973.0T 2010-07-21 2011-07-21 Sól i solwaty pochodnej tetrahydroizochinoliny PL2595960T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36636710P 2010-07-21 2010-07-21

Publications (1)

Publication Number Publication Date
PL2595960T3 true PL2595960T3 (pl) 2016-09-30

Family

ID=44386640

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11740973.0T PL2595960T3 (pl) 2010-07-21 2011-07-21 Sól i solwaty pochodnej tetrahydroizochinoliny

Country Status (19)

Country Link
US (3) US8614227B2 (pl)
EP (2) EP2595960B1 (pl)
JP (3) JP5948326B2 (pl)
CN (2) CN103003244B (pl)
AU (3) AU2011281381B2 (pl)
CA (1) CA2803699C (pl)
DK (1) DK2595960T3 (pl)
ES (1) ES2570135T3 (pl)
HK (1) HK1224290A1 (pl)
HR (1) HRP20160540T1 (pl)
HU (1) HUE028620T2 (pl)
ME (1) ME02407B (pl)
NZ (2) NZ605444A (pl)
PL (1) PL2595960T3 (pl)
PT (1) PT2595960E (pl)
SI (1) SI2595960T1 (pl)
SM (1) SMT201600171B (pl)
WO (1) WO2012010843A1 (pl)
ZA (1) ZA201300169B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160540T1 (hr) * 2010-07-21 2016-06-17 Novartis Ag Sol i solvati jednog derivata tetrahidroizokinolina
US9320530B2 (en) * 2013-03-13 2016-04-26 The Spectranetics Corporation Assisted cutting balloon
EP3019477B1 (en) * 2013-07-08 2021-05-26 Novartis AG Heterocyclic compounds and methods of their use
JP6667551B2 (ja) 2015-01-13 2020-03-18 ノバルティス アーゲー アンジオテンシンii2型拮抗薬としてのピロリジン誘導体
WO2016142867A1 (en) 2015-03-12 2016-09-15 Novartis Ag Heterocyclic compounds and methods for their use
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
US20190152918A1 (en) 2016-06-27 2019-05-23 Ratiopharm Gmbh Crystalline calcium salt of (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid
JP2019514862A (ja) * 2017-03-23 2019-06-06 ノバルティス アーゲー (s)−2−(ジフェニルアセチル)−1,2,3,4−テトラヒドロ−6−メトキシ−5−(フェニルメトキシ)−3−イソキノリンカルボン酸ナトリウムの無水結晶形
PT3620454T (pt) * 2017-06-09 2021-09-10 Shandong Danhong Pharmaceutical Co Ltd Derivado de ácido carboxílico como antagonista do recetor at2r
US11198861B2 (en) 2018-07-12 2021-12-14 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
WO2020012266A1 (en) 2018-07-12 2020-01-16 Novartis Ag Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase
CN111620816B (zh) * 2020-05-27 2023-06-02 上海赛默罗生物科技有限公司 螺桨烷类衍生物、其制备方法、药物组合物和用途
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US6300356B1 (en) * 1998-02-25 2001-10-09 Merck & Co., Inc. Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
EP2650011A1 (en) 2004-12-24 2013-10-16 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
CN102885818B (zh) 2006-03-20 2016-05-04 诺华股份有限公司 治疗或预防炎性痛的方法
CN107744519A (zh) * 2010-01-19 2018-03-02 诺华股份有限公司 改良神经传导速度的方法和组合物
HRP20160540T1 (hr) * 2010-07-21 2016-06-17 Novartis Ag Sol i solvati jednog derivata tetrahidroizokinolina

Also Published As

Publication number Publication date
US8614227B2 (en) 2013-12-24
US20140080865A1 (en) 2014-03-20
WO2012010843A1 (en) 2012-01-26
ME02407B (me) 2016-09-20
CA2803699A1 (en) 2012-01-26
AU2011281381A1 (en) 2013-01-10
JP5948326B2 (ja) 2016-07-06
US20150105422A1 (en) 2015-04-16
US20120022101A1 (en) 2012-01-26
AU2015238774A1 (en) 2015-10-29
EP2595960A1 (en) 2013-05-29
HK1224290A1 (en) 2017-08-18
ZA201300169B (en) 2016-03-30
DK2595960T3 (en) 2016-05-09
JP2013531057A (ja) 2013-08-01
CA2803699C (en) 2016-05-31
AU2011281381B2 (en) 2015-07-16
PT2595960E (pt) 2016-06-02
HUE028620T2 (en) 2016-12-28
SMT201600171B (it) 2016-07-01
CN103003244A (zh) 2013-03-27
JP2017214415A (ja) 2017-12-07
EP3081557A1 (en) 2016-10-19
CN103003244B (zh) 2016-04-20
CN105777636A (zh) 2016-07-20
NZ708529A (en) 2016-11-25
SI2595960T1 (sl) 2016-06-30
HRP20160540T1 (hr) 2016-06-17
AU2017203236A1 (en) 2017-06-08
JP2016164178A (ja) 2016-09-08
EP2595960B1 (en) 2016-02-24
NZ605444A (en) 2015-06-26
US9162985B2 (en) 2015-10-20
ES2570135T3 (es) 2016-05-17
US8927575B2 (en) 2015-01-06

Similar Documents

Publication Publication Date Title
ZA201300169B (en) Salt and solvates of a tetrahydroisoquinoline derivative
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
ZA201209205B (en) Pyridone and aza-pyridone compounds and methods of use
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
HUE038574T2 (hu) Adagkapszula és adagkapszula alkalmazása
IL220939A0 (en) Compounds and methods
EP2523664A4 (en) COMPOUNDS AND METHODS
PL2623497T3 (pl) Sól megluminowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu
ZA201301120B (en) Heterocyclic compound and use thereof
SI2623498T1 (sl) Natrijeva sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida
IL220812A0 (en) Compounds and methods
AP3917A (en) Subsea anchor
GB201018124D0 (en) Polymorphs and salts
EP2523560A4 (en) CONNECTIONS AND METHODS
EP2594554A4 (en) BIARYLAMID DERIVATIVES BZW. PHARMACEUTICALLY PERMITTED SALT FROM THIS
GB201006680D0 (en) Alarm
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
PT2552910E (pt) Novo polimorfo
ZA201400248B (en) Synthesis of cleistainthin a and derivatives thereof
AP2012006419A0 (en) Aminoquinoline derivatives
GB201004450D0 (en) Compounds and methods relating thereto
IL225708A0 (en) Methods for the synthesis of scylitol and related compounds
HK1180343A (en) Salt and solvates of a tetrahydroisoquinoline derivative
HU1000688D0 (en) Use of trifluoro-phal
TWM389317U (en) Personal effects alarm